EssilorLuxottica Ramps Up Washington Presence Amid Trade and Regulatory Shifts
*** filed its First Quarter 2026 lobbying disclosure on April 9, 2026, reporting $150,000 in in-house lobbying expenditures. The filing continues a sustained federal engagement strategy that has totaled approximately $1.12 million across 14 quarterly disclosures over the past two years.
---
Why It Matters
EssilorLuxottica USA Inc., the world's largest eyewear company, operates at the intersection of U.S. trade policy, vision care access legislation, and medical device regulation. The company faces significant exposure to proposed tariffs—including up to 145 percent on China-manufactured goods and 36 percent on Thailand-made products—that directly affect its supply chain. Simultaneously, Congress has advanced legislation on vision care access and optical lab choice, while the FDA authorized the company's myopia-control lens technology in September 2025. These converging policy pressures explain why the company has maintained consistent federal engagement despite the Q1 2026 filing's lack of specific legislative targets.
---
By the Numbers
EssilorLuxottica's first quarter 2026 lobbying disclosure reports $150,000 in spending—matching higher quarterly spend levels from second quarter 2025 ($150,000) and last quarter 2025 ($150,000), and exceeding first and third quarters in 2025 at $130,000.
Over the past two years, the company's lobbying expenditures break down as follows:
- 2024: Four quarterly filings totaling $560,000Second quarter $150,000; Third quarter: $130,000; Final quarter: $130,000; plus earlier filings)
- 2025: Four quarterly filings totaling $560,000
- 2026 (First quarter): $150,000
Total across 14 filings (April 2024–April 2026): $1.12 million
According to OpenSecrets, EssilorLuxottica spent $410,000 on federal lobbying in 2025 alone.
All lobbying is conducted in-house. Tillie Fowler serves as the sole registered lobbyist. Fowler previously served as Chief of Staff to Rep. Virginia Brown-Waite (R-FL-5) during the 110th Congress and holds a Juris Doctor from American University Washington College of Law. There is no indication the company has hired outside lobbying firms or changed its lobbying team in recent quarters.
---
The Agenda
The first quarter 2026 EssilorLuxottica lobbying disclosure does not list any specific legislation or issues.
This represents a shift from prior quarters, where EssilorLuxottica disclosed specific legislative priorities. Recent filings reference:
- HR 1521 – DOC Access Act of 2025 (Q2 2025) — likely addressing direct-to-consumer access to vision services
- S. 1716 – Vision Lab Choice Act of 2025 (Q3 and Q4 2025) — would allow consumers to obtain prescription lenses from independent optical labs rather than exclusive in-house suppliers
- H.R. 2748/S. 4083 – Contact Lens Prescription Verification Modernization Act (Q2 2024) — modernizing contact lens prescription rules
Whether any of these priorities remain active is unclear from the current disclosure.
---
Broader Context
EssilorLuxottica's lobbying activity takes place amid significant policy developments affecting its core business.
Trade and Tariffs: In April 2025, Reuters reported that EssilorLuxottica faced potential tariffs of up to 36 percent on Thailand-made products, 145 percent on goods from China, and up to 20 percent on European imports. The company's CEO subsequently stated the company could move part of its production to the United States in response. The company also raised U.S. prices to offset tariff impacts.
Congress has weighed in on these issues. Sen. Jeanne Shaheen's April 16, 2025 letter specifically identified optical instruments as a vulnerable supply chain sector, noting that such industries "source a large part of their components from outside North America." A bipartisan Senate resolution from September 2025, led by Sens. Paul, Kaine, Schumer, Shaheen, and Wyden, challenged the president's authority to impose tariffs unilaterally under the International Emergency Economic Powers Act (IEEPA).
FDA Medical Device Authorization: On September 25, 2025, the FDA authorized EssilorLuxottica's Essilor Stellest lens—the first-ever FDA-authorized spectacle lens to slow myopia progression in children. This landmark authorization opens questions around insurance coverage, Medicare/Medicaid reimbursement, and pediatric health policy that could drive federal engagement.
Antitrust Litigation: Reuters reported in September 2025 that a federal judge dismissed consumer lawsuits alleging EssilorLuxottica monopolized markets for designer frames and prescription lenses. Plaintiffs were granted leave to refile, however, meaning the litigation environment remained active heading into 2026.
---
The Bottom Line
EssilorLuxottica's first quarter 2026 filing maintains the company's Washington footprint at consistent spending levels, though the blank issues field provides little visibility into current legislative priorities. The company continues to rely on in-house lobbying with a single registered lobbyist and no outside firms. The broader policy environment—spanning tariff disputes, vision care access legislation, FDA medical device regulation, and ongoing antitrust scrutiny—provides ample reason for continued federal engagement. Whether this quarter's generic filing approach reflects a deliberate strategy shift or simply a lull in specific legislative targeting will become clearer in subsequent quarterly disclosures.